Washington University School of Medicine has discovered a new approach to developing painkillers that don’t cause addiction or hallucinations, by targeting specific binding sites on the kappa opioid receptor and understanding the interaction of G proteins linked to the receptor. This could lead to safer pain-relieving drugs.


